Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
The Pharma Data
JUNE 17, 2022
2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.
Let's personalize your content